Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a/1b study of INCB081776 alone and with INCMGA00012 in advanced malignancies
NL-OMON52063Phase 1Recruiting
- Sponsor
- Incyte
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of INCB081776 and retifanlimab in Nonhematologic neoplasms, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 9 more, sponsored by Incyte. Primary endpoints: Safety and tolerability and Recommended dose for expansion. Started Oct 2022; status: recruiting.
02
Drugs
INCB081776retifanlimab
03
Conditions
Nonhematologic neoplasmsgastric adenocarcinomagastroesophageal junction adenocarcinomahepatocellular carcinoma (HCC)melanoma
Beyond the preview
Go deeper on NL-OMON52063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52063.